Year 2021 / Volume 113 / Number 2
Letter
Effectiveness and safety of switching to adalimumab biosimilar ABP 501 in Crohn’s disease: the extrapolation concept

155

DOI: 10.17235/reed.2020.7253/2020

Davide Giuseppe Ribaldone, Marta Vernero, Marco Astegiano,

Abstract
We sincerely thank Viscido et al. for their appropriate and sharable comments on our recent study on adalimumab biosimilar ABP 501 in Crohn’s disease (CD). The use of a biosimilar in inflammatory disorders is one of the current main topics, given the great opportunity to save resources that can be invested in innovative drugs and the ethical problems that non-medical switching can generate.
Share Button
New comment
Comments
No comments for this article
References
1. Viscido A, Latella G. Effectiveness and safety of switching to adalimumab biosimilar ABP 501 in Crohn’s disease. Rev Esp Enferm Dig 2020;
2. Ribaldone DG, Caviglia GP, Pellicano R, et al. Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn's disease: an observational study. Rev Esp Enferm Dig 2020; 112: 195-200. DOI: 10.17235/reed.2020.6693/2019.
3. Dolinar R1, Kohn CG2, Lavernia F, et al. The non-medical switching of prescription medications. Postgrad Med. 2019 Jun;131(5):335-341.
4. Wolff-Holz E, Tiitso K, Vleminckx C et al. Evolution of the EU Biosimilar Framework: Past and Future. BioDrugs. 2019 Dec;33(6):621-634.
Related articles

Letter

Hepatosplenic T-cell lymphoma and inflammatory bowel disease

DOI: 10.17235/reed.2023.9472/2023

Review

Clinical settings with tofacitinib in ulcerative colitis

DOI: 10.17235/reed.2022.8660/2022

Letter

Anal neoplasia and perianal Crohn’s disease: myth or reality?

DOI: 10.17235/reed.2021.8317/2021

Letter

Apoptotic colopathy as a manifestation of Good’s syndrome

DOI: 10.17235/reed.2021.8297/2021

Original

Radon exposure and inflammatory bowel disease in a radon prone area

DOI: 10.17235/reed.2021.8239/2021

Review

Inflammatory bowel disease and solid organ transplantation

DOI: 10.17235/reed.2020.7361/2020

Editorial

Is celiac disease really associated with inflammatory bowel disease?

DOI: 10.17235/reed.2019.6779/2019

Original

Megacolon in inflammatory bowel disease: response to infliximab

DOI: 10.17235/reed.2020.6394/2019

Editorial

Diet in the etiology of inflammatory bowel disease

DOI: 10.17235/reed.2018.6119/2018

Case Report

Serrated Lesions in patients with Inflammatory Bowel Disease.

DOI: 10.17235/reed.2019.5910/2018

Editorial

Online social networks and inflammatory bowel disease

DOI: 10.17235/reed.2018.5496/2018

Letter to the Editor

Idiopathic portal hypertension with regard to thiopurine treatment

DOI: 10.17235/reed.2018.5256/2017

Editorial

Specialist care in the management of inflammatory bowel disease

DOI: 10.17235/reed.2016.4628/2016

Citation tools
Ribaldone D, Vernero M, Astegiano M. Effectiveness and safety of switching to adalimumab biosimilar ABP 501 in Crohn’s disease: the extrapolation concept. 7253/2020


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 858 visits.
This article has been downloaded 134 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 12/05/2020

Accepted: 13/05/2020

Online First: 19/11/2020

Published: 08/02/2021

Article Online First time: 191 days

Article editing time: 272 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology